Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Nephropathies

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44412   clinical trials with a EudraCT protocol, of which   7421   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    100 result(s) found for: Nephropathies. Displaying page 1 of 5.
    1  2  3  4  5  Next»
    EudraCT Number: 2008-001647-19 Sponsor Protocol Number: 2008.1 Start Date*: 2008-05-22
    Sponsor Name:Radboud University Nijmegen Medical Center
    Full Title: Treatment with synthetic adrenocoticotropic hormone (ACTH) in patients with membranous nephropathy and high risk for renal failure. A pilot study.
    Medical condition: Membranous nephropathy
    Disease: Version SOC Term Classification Code Term Level
    9.1 10027170 Membranous nephropathy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-004467-65 Sponsor Protocol Number: DNTx Start Date*: 2007-04-24
    Sponsor Name:Technical University Dresden
    Full Title: Influence of pioglitazone for renal transplant function in diabetics
    Medical condition: nephropathy after renal transplantation in patients with type 2 diabetes
    Disease: Version SOC Term Classification Code Term Level
    8.1 10061835 Diabetic nephropathy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2020-002985-15 Sponsor Protocol Number: MOR202C205 Start Date*: 2020-10-12
    Sponsor Name:MorphoSys AG
    Full Title: A Phase IIa, Open-Label, 2-Arm Multicenter Clinical Trial to Evaluate the Efficacy, Safety and PK/PD of the Human Anti-CD38 Antibody MOR202 in Anti-PLA2R Antibody Positive Membranous Nephropathy (N...
    Medical condition: Anti-PLA2R antibody positive membranous nephropathy (aMN)
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004857 10027170 Membranous nephropathy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2011-006115-59 Sponsor Protocol Number: GNM-2011 Start Date*: 2012-06-11
    Sponsor Name:AZIENDA OSPEDALIERA SPEDALI CIVILI DI BRESCIA
    Full Title: "A Randomized Controlled Trial of Rituximab Versus Steroids and Cyclophosphamide in the Treatment of Idiopathic Membranous Nephropathy (IMN)"
    Medical condition: MN is an autoimmune disease, suggesting that the disease may be triggered by isotype specific autoantibodies directed against podocyte enzymes and podocyte receptors that are recognized as antigens...
    Disease: Version SOC Term Classification Code Term Level
    14.1 10038359 - Renal and urinary disorders 10018372 Glomerulonephritis membranous PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-005410-39 Sponsor Protocol Number: MEMTAC Start Date*: 2008-06-11
    Sponsor Name:Grupo Catalán de Estudio de enfermedades glomerulares. Sociedad Catalana de nefrología.
    Full Title: “Estudio piloto aleatorizado comparativo de tacrolimus vs ciclofosfamida-prednisona en la nefropatía membranosa idiopática”
    Medical condition: La nefropatía membranosa idiopática (NMI) es una enfermedad caracterizada histopatológicamente por un engrosamiento uniforme de la pared de los capilares glomerulares, debido al depósito de complej...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10027170 Membranous nephropathy LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-000835-30 Sponsor Protocol Number: MONET Start Date*: 2021-10-12
    Sponsor Name:IRCCS- ISTITUTO DI RICERCHE FARMACOLOGICHE MARIO NEGRI
    Full Title: RESCUE THERAPY WITH THE HUMAN ANTI-CD38 ANTIBODY MOR202 (FELZARTAMAB) IN PATIENTS WITH MEMBRANOUS NEPHROPATHY WHO FAILED ANTI-CD20 TARGETED THERAPY: A PILOT, PROOF-OF-CONCEPT STUDY
    Medical condition: Membranous Nephropathy who Failed Anti-CD20 Target Therapy.
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004857 10027170 Membranous nephropathy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-004864-81 Sponsor Protocol Number: ORION Start Date*: 2021-12-17
    Sponsor Name:IRCCS- ISTITUTO DI RICERCHE FARMACOLOGICHE MARIO NEGRI
    Full Title: Proposta di studio per valutare l’efficacia di Obinutuzumab, un anticorpo anti-CD20, in pazienti con nefropatia membranosa intolleranti, resistenti o dipendenti alla terapia con Rituximab (studio O...
    Medical condition: PRIMARY MEMBRANOUS NEPHROPATHY
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004857 10027170 Membranous nephropathy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2018-002476-40 Sponsor Protocol Number: 17-APN-01 Start Date*: 2019-05-07
    Sponsor Name:CHU de Nice
    Full Title: Personalized Medicine for Membranous Nephropathy PMMN
    Medical condition: Idiopathic Membranous Nephropathy
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004857 10027170 Membranous nephropathy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-000786-32 Sponsor Protocol Number: SPP301CRD21 Start Date*: 2008-06-17
    Sponsor Name:Speedel Pharma Ltd
    Full Title: A Randomised, Double-blind, Placebo-Controlled, Dose-ranging, Parallel Design Study to Evaluate the Efficacy and Safety of the Endothelin Antagonist Avosentan in Patients With Diabetic Kidney Disease
    Medical condition: Diabetic kidney disease
    Disease: Version SOC Term Classification Code Term Level
    9.1 10012687 Diabetic renal disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed) BE (Completed) LV (Prematurely Ended) CZ (Prematurely Ended) HU (Prematurely Ended) DE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2016-002262-31 Sponsor Protocol Number: MS700461-0035 Start Date*: 2017-03-17
    Sponsor Name:Merck KGaA
    Full Title: A Phase II Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Atacicept in IgA Nephropathy
    Medical condition: IgA Nephropathy
    Disease: Version SOC Term Classification Code Term Level
    20.1 10038359 - Renal and urinary disorders 10061835 Diabetic nephropathy PT
    20.0 10038359 - Renal and urinary disorders 10021263 IgA nephropathy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2016-000722-19 Sponsor Protocol Number: M12-919 Start Date*: 2016-10-24
    Sponsor Name:AbbVie Deutschland GmbH & Co. KG
    Full Title: A Multicenter, Single-Arm Study of the Effects of Atrasentan on Spermatogenesis and Testicular Function
    Medical condition: Diabetic Nephropathy
    Disease: Version SOC Term Classification Code Term Level
    19.0 10038359 - Renal and urinary disorders 10061835 Diabetic nephropathy PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: DE (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2021-003053-37 Sponsor Protocol Number: 21952 Start Date*: 2021-11-05
    Sponsor Name:Bayer AG
    Full Title: A non-blinded retrospective biomarker add-on study to FIGARO-DKD for Bioprofiling the pharMacodynamic response to finerenone in FIGARO-DKD subjects (FIGARO-BM)
    Medical condition: Type II Diabetes Mellitus and Diabetic Kidney Disease
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038359 - Renal and urinary disorders 10061835 Diabetic nephropathy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BG (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2020-005855-19 Sponsor Protocol Number: BCX9930-211 Start Date*: 2021-10-11
    Sponsor Name:BioCryst Pharmaceuticals Inc
    Full Title: An Open-Label, Safety, Tolerability, and Proof-of-Concept Study of Oral BCX9930 Therapy in Subjects with Complement 3 Glomerulopathy, Immunoglobulin A Nephropathy, or Primary Membranous Nephropathy
    Medical condition: complement 3 glomerulopathy immunoglobulin A nephropathy primary membranous nephropathy
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038359 - Renal and urinary disorders 10021263 IgA nephropathy PT
    21.1 10038359 - Renal and urinary disorders 10027170 Membranous nephropathy LLT
    20.0 10038359 - Renal and urinary disorders 10077827 C3 glomerulopathy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended) IT (Prematurely Ended) HU (Completed)
    Trial results: View results
    EudraCT Number: 2012-005482-12 Sponsor Protocol Number: GLP-1-2012-01 Start Date*: 2013-04-15
    Sponsor Name:University College Dublin
    Full Title: The effect of glucagon-like-peptide 1 (GLP-1) analogues on inflammation in humans with diabetic kidney disease.
    Medical condition: Diabetic Kidney Disease
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004857 10012687 Diabetic renal disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Completed)
    Trial results: View results
    EudraCT Number: 2006-002328-40 Sponsor Protocol Number: HHSC/005 Start Date*: 2007-05-18
    Sponsor Name:Imperial College London
    Full Title: A phase I safety and tolerability study of infusing the autologous progeny of an adult CD34+ subset into patients with type I diabetes mellitus and a successful renal transplant.
    Medical condition: Diabetes mellitus type 1 and succesful renal transplant
    Disease: Version SOC Term Classification Code Term Level
    9.1 10012638 Diabetes with renal manifestations LLT
    9.1 10038533 Renal transplant LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2012-002480-98 Sponsor Protocol Number: MT-3995-E06 Start Date*: 2012-10-26
    Sponsor Name:Mitsubishi Tanabe Pharma Corporation (MTPC)
    Full Title: A Randomised, Double-blind, Placebo-controlled Study to Evaluate the Effect on Urine Albumin-to-Creatinine Ratio (UACR), Pharmacodynamics, Safety, Tolerability and Pharmacokinetics of Multiple Oral...
    Medical condition: Type II Diabetes Mellitus with Nephropathy and Albuminuria
    Disease: Version SOC Term Classification Code Term Level
    17.0 10038359 - Renal and urinary disorders 10061835 Diabetic nephropathy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) LT (Completed) SK (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2007-005985-10 Sponsor Protocol Number: PTF-REN-001 Start Date*: 2008-03-03
    Sponsor Name:Juan Francisco Navarro González
    Full Title: Análisis del Efecto Renoprotector de la Pentoxifilina en Pacientes con Enfermedad Renal Crónica Secundaria a Nefropatía Diabética
    Medical condition: Enfermedad renal crónica secundaria a nefropatía diabética.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10061835 Diabetic nephropathy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-004523-19 Sponsor Protocol Number: TIP0305 Start Date*: 2008-02-08
    Sponsor Name:Área de Trasplante y Terapia Celular - Hospital Central de Asturias
    Full Title: Phase II clinical trial to evaluate the efficacy and safety in the use of pancreatic islets cells from cadaver donors for the treatment of Type-I Diabetes Mellitus in renal transplant patients.
    Medical condition: Type-I Diabetes Mellitus in renal trasplant patients
    Disease: Version SOC Term Classification Code Term Level
    8.1 10061835 pt
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-003618-17 Sponsor Protocol Number: ALT-711-0424 Start Date*: 2008-05-07
    Sponsor Name:JDRF Danielle Alberti Memorial Centre For Diabetes Complications Baker Heart Research Institute
    Full Title: A Randomozed, Placebo-Controlled Trial of Alagebrium in Patients with Insulin-Dependent Type 1 Diabetes and Microalbuminuria
    Medical condition: This is a double-blind phase 2 clinical study to evaluate the effects of alagebrium chloride (ALT-711) versus placebo on albumin excretion rate (as an early marker of diabetic nephropathy) in subje...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10061835 Diabetic nephropathy LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2010-019206-16 Sponsor Protocol Number: EBP-FHC-2010-3 Start Date*: 2010-05-12
    Sponsor Name:Medicinsk Forskning, Regionshospitalet Holstebro
    Full Title: Effekten af atorvastatin på NO-systemet patienter med type 2 diabetes med nefropati
    Medical condition: Diabetisk Nefropati Formålet er at måle effekten af atorvastatin på L-NMMA inducerede ændringer i den renale tubulære transport af natrium og vand , central hæmodynamik og vasoaktive hormoner hos...
    Disease: Version SOC Term Classification Code Term Level
    12.1 10012638 Diabetes with renal manifestations LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri Oct 16 08:35:00 CEST 2026 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA